The study, led by TSRI’s Patricia McDonald and Richard Lerner, may lead to a new type of diabetes treatment.
These detailed “fingerprints” developed by the Martemyanov lab show surprising complexity in how GPCRs activate their binding partners.
The findings from the Millar lab advance drug development.
"We want to avoid landfills," says Peter Norris, director of Scripps Florida EH&S.